Transpire Bio Enters into Exclusive License Agreement with Suzhou Intragrand Pharma for Investigational PDE4 Inhibitor

News Transpire Bio Enters into Exclusive License Agreement with Suzhou Intragrand Pharma for Investigational PDE4 Inhibitor WESTON, Jun 03, 2025 (GLOBE NEWSWIRE) — Transpire Bio Inc., a U.S.-based, integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that it has signed an exclusive license agreement with Suzhou Intragrand […]